Association between cardiotrophin 1 levels and central blood pressure in untreated patients with essential hypertension

American Journal of Hypertension

Volumn 27, Issue 5, 2014, Pages 651-655

  Gkaliagkousi, Eugenia ^a   Gavriilaki, Eleni ^a   Nikolaidou, Barbara ^a   Chatzopoulou, Fani ^a   Anyfanti, Panagiota ^a   Triantafyllou, Areti ^a   Petidis, Konstantinos ^a   Zamboulis, Chrysanthos ^a   Douma, Stella ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

arterial stiffness; blood pressure; cardiotrophin 1; central blood pressure; essential hypertension; hypertension.

Indexed keywords

CARDIOTROPHIN 1; BIOLOGICAL MARKER; CYTOKINE;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE MONITORING; CENTRAL BLOOD PRESSURE; CLINICAL ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; ENZYME LINKED IMMUNOSORBENT ASSAY; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; RIGIDITY; SYSTOLIC BLOOD PRESSURE; TONOMETRY; ARTERIAL STIFFNESS; BLOOD; CASE CONTROL STUDY; HYPERTENSION; MANOMETRY; MIDDLE AGED; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PROGNOSIS; PULSE WAVE; UPREGULATION;

ADULT; BIOLOGICAL MARKERS; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; CASE-CONTROL STUDIES; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; HYPERTENSION; MALE; MANOMETRY; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PULSE WAVE ANALYSIS; UP-REGULATION; VASCULAR STIFFNESS;

EID: 84898853178     PISSN: 08957061     EISSN: 19417225     Source Type: Journal    
DOI: 10.1093/ajh/hpt238     Document Type: Article

References (23)

1. Pennica D, King KL, Shaw KJ, Luis E, Rullamas J, Luoh SM, Darbonne WC, Knutzon DS, Yen R, Chien KR. Expression cloning of cardiotro-phin 1, a cytokine that induces cardiac myocyte hypertrophy. Proc Natl Acad Sci USA 1995; 92:1142-1146.
2. Jougasaki M, Tachibana I, Luchner A, Leskinen H, Redfeld MM, Burnett JC, Jr. Augmented cardiac cardiotrophin-1 in experimental congestive heart failure. Circulation 2000; 101:14-17.
3. Lopez N, Diez J, Fortuno MA. Diferential hypertrophic efects of car-diotrophin-1 on adult cardiomyocytes from normotensive and spontaneously hypertensive rats. J Mol Cell Cardio 2006; 41:902-913.
4. Ishikawa M, Saito Y, Miyamoto Y, Harada M, Kuwahara K, Ogawa E, Nakagawa O, Hamanaka I, Kajiyama N, Takahashi N, Masuda I, Hashimoto T, Sakai O, Hosoya T, Nakao K. A heart-specifc increase in cardiotrophin-1 gene expression precedes the establishment of ven tricular hypertrophy in genetically hypertensive rats. J Hypertens 1999; 17:807-816.
5. Lopez-Andres N, Fortuno MA, Diez J, Zannad F, Lacolley P, Rossignol P. Vascular efects of cardiotrophin-1: a role in hypertension? J Hypertens 2010; 28:1261-1272.
6. Lopez-Andres N, Martin-Fernandez B, Rossignol P, Zannad F, Lahera V, Fortuno MA, Cachofeiro V, Diez J. A role for cardiotrophin-1 in myocardial remodeling induced by aldosterone. Am J Physiol 2011; 301:H2372-H2382.
7. Lopez-Andres N, Rousseau A, Akhtar R, Calvier L, Inigo C, Labat C, Zhao X, Cruickshank K, Diez J, Zannad F, Lacolley P, Rossignol P. Cardiotrophin 1 is involved in cardiac, vascular, and renal fbrosis and dysfunction. Hypertension 2012; 60:563-573.
8. Lopez-Andres N, Calvier L, Labat C, Fay R, Diez J, Benetos A, Zannad F, Lacolley P, Rossignol P. Absence of cardiotrophin 1 is associated with decreased age-dependent arterial stifness and increased longevity in mice. Hypertension 2013; 61:120-129.
9. Pemberton CJ, Raudsepp SD, Yandle TG, Cameron VA, Richards AM. Plasma cardiotrophin-1 is elevated in human hypertension and stimu lated by ventricular stretch. Cardiovasc Res 2005; 68:109-117.
10. Lopez B, Gonzalez A, Lasarte JJ, Sarobe P, Borras F, Diaz A, Barba J, Tomas L, Lozano E, Serrano M, Varo N, Beloqui O, Fortuno MA, Diez J. Is plasma cardiotrophin-1 a marker of hypertensive heart disease? J Hypertens 2005; 23:625-632.
11. Lopez B, Castellano JM, Gonzalez A, Barba J, Diez J. Association of increased plasma cardiotrophin-1 with inappropriate lef ventricular mass in essential hypertension. Hypertension 2007; 50:977-983.
12. Gonzalez A, Lopez B, Martin-Raymondi D, Lozano E, Varo N, Barba J, Serrano M, Diez J. Usefulness of plasma cardiotrophin-1 in assessment of lef ventricular hypertrophy regression in hypertensive patients. J Hypertens 2005; 23:2297-2304.
13. Ravassa S, Beloqui O, Varo N, Barba J, Lopez B, Beaumont J, Zalba G, Diez J, Gonzalez A. Association of cardiotrophin-1 with lef ventricular systolic properties in asymptomatic hypertensive patients. J Hypertens 2013; 31:587-594.
14. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, Christiaens T, Cifova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F, Burnier M, Ambrosioni E, Caufeld M, Coca A, Olsen MH, Tsioufs C, van de Borne P, Zamorano JL, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol C, Ferrari R, Hasdai D, Hoes AW, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Tamargo JL, Tendera M, Torbicki A, Wijns W, Windecker S, Clement DL, Gillebert TC, Rosei EA, Anker SD, Bauersachs J, Hitij JB, Caulfeld M, De Buyzere M, De Geest S, Derumeaux GA, Erdine S, Farsang C, Funck-Brentano C, Gerc V, Germano G, Gielen S, Haller H, Jordan J, Kahan T, Komajda M, Lovic D, Mahrholdt H, Ostergren J, Parati G, Perk J, Polonia J, Popescu BA, Reiner Z, Ryden L, Sirenko Y, Stanton A, Struijker-Boudier H, Vlachopoulos C, Volpe M, Wood DA. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013; 34:2159-2219.
15. Laurent S, Cockcrof J, Van Bortel L, Boutouyrie P, Giannattasio C, Hayoz D, Pannier B, Vlachopoulos C, Wilkinson I, Struijker-Boudier H. Expert consensus document on arterial stifness: methodological issues and clinical applications. Eur Heart J 2006; 27:2588-2605.
16. Roman MJ, Devereux RB, Kizer JR, Lee ET, Galloway JM, Ali T, Umans JG, Howard BV. Central pressure more strongly relates to vascular disease and outcome than does brachial pressure: the Strong Heart Study. Hypertension 2007; 50:197-203.
17. Wang KL, Cheng HM, Chuang SY, Spurgeon HA, Ting CT, Lakatta EG, Yin FC, Chou P, Chen CH. Central or peripheral systolic or pulse pressure: which best relates to target organs and future mortality? J Hypertens 2009; 27:461-467.
18. Jankowski P, Kawecka-Jaszcz K, Czarnecka D, Brzozowska-Kiszka M, Styczkiewicz K, Styczkiewicz M, Posnik-Urbanska A, Bryniarski L, Dudek D. Ascending aortic, but not brachial blood pressure-derived indices are related to coronary atherosclerosis. Atherosclerosis 2004; 176:151-155.
19. Jankowski P, Kawecka-Jaszcz K, Czarnecka D, Brzozowska-Kiszka M, Styczkiewicz K, Loster M, Kloch-Badelek M, Wilinski J, Curylo AM, Dudek D. Pulsatile but not steady component of blood pressure predicts cardiovascular events in coronary patients. Hypertension 2008; 51:848-855.
20. Pini R, Cavallini MC, Palmieri V, Marchionni N, Di Bari M, Devereux RB, Masotti G, Roman MJ. Central but not brachial blood pressure predicts cardiovascular events in an unselected geriatric population: the ICARe Dicomano Study. J Am Coll Cardiol 2008; 51:2432-2439.
21. Williams B, Lacy PS, Tom SM, Cruickshank K, Stanton A, Collier D, Hughes AD, Turston H, O'Rourke M. Diferential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006; 113:1213-1225.
22. Mahmud A, Feely J. Arterial stifness is related to systemic infamma-tion in essential hypertension. Hypertension 2005; 46:1118-1122.
23. Weinhold B, Ruther U. Interleukin-6-dependent and-independent regulation of the human C-reactive protein gene. Biochem J 1997; 327:425-429.